Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls - Barthel, H; Luthardt, J; Becker, G (Eur J Nucl Med Mol Imaging)
et al.